Clinical trial

Comparison of the Effects of Isotonic and Hypotonic Intravenous Maintenance Fluids on Term Neonatal Babies Undergoing Intravenous Fluid Therapy: Multicenter Observational Neofluid Study

Name
363-SBKAEK
Description
Considering the physiological changes in fluid and electrolyte balance and providing proper support are one of the important aspects of neonatal intensive care. Maintenance intravenous fluids are designed to maintain homeostasis when a patient is unable to uptake required water, electrolytes, and energy. Hypotonic fluids are still the most commonly prescribed IV fluids for pediatric hospitalized patients. However, previous studies, including children older than one month of age revealed that traditionally used hypotonic fluids may lead to hyponatremia. Because of the absence of evidence-based data, there is currently no clear consensus on the optimal composition of maintenance intravenous fluid therapy in newborns, leading to wide practice variation. The National Clinical Guideline Center (NICE) 2015 recommends the use of isotonic fluids in term newborn infants and some newborn centers has begun to use isotonic fluids since guidelines recommendations. Since the publication of the NICE guideline, no studies have addressed this topic. In this prospective, observational , multicentric study, conventional hypotonic fluids containing sodium chloride (NaCl) \< 130 mmol/L compared with isotonic fluids (containing NaCl between 131-154 mmol/L) in terms of the risk of hyponatremia, hypernatremia, plasma sodium (pNa) level change, treatment morbidities, hospitalization duration and mortality.
Trial arms
Trial start
2020-12-30
Estimated PCD
2022-12-31
Trial end
2023-06-30
Status
Completed
Treatment
Intravenous isotonic fluid - NaCl 131-154 mmol/L in 5% dextrose
Isotonic group will be given fluids containing 131-154 mmol/L Sodium Chloride
Arms:
Isotonic fluid
Other names:
B05BB02, 0.9% NaCl/Dextrose 5%
Intravenous Hypotonic fluid- Sodium Chloride < 130 mmol/L
Hypotonic group will be given fluids containing lower than 130 mmol/L : Dextrose 5% in 0.2% Sodium Chloride, or Dextrose 5% in 0.33 % Sodium Chloride,or Dextrose 5% in %0.45 Sodium Chloride, or Intravenous fluid containing Sodium Chloride \< 130 mmol/L
Arms:
Hypotonic fluid
Other names:
B05BB02, 0.45% NaCl/5% dextrose, B05BB02, 0.33 % NaCl/5% dextrose, B05BB02, 0.20 % NaCl/5% dextrose
Size
420
Primary endpoint
Change in mean plasma Na
24 hours after the intervention
Rate of development of hyponatremia
during the intervention
Rate of development of hypernatremia
during the intervention
Eligibility criteria
Inclusion Criteria are: * Term newborns (\>37 + 0/7 weeks) aged 24 hours to 30 days with a normal baseline serum sodium level between 135-145 mmol/L,with a treatment plan to include IV fluids at \> 50% of maintenance * Infants not received parenteral fluids in the last 24 hours before participation * Infants receiving IV fluid administration at 50% to 100% of maintenance Exclusion Criteria: * Newborns with diagnoses that required specific fluid tonicity and volumes such as: * Severe dehydration presenting with shock * Syndrome of inappropriate antidiuretic hormone secretion (SIADH) * Renal insufficiency * Adrenal insufficiency * Diabetes mellitus and diabetes insipidus * Hypoxic ischemic encephalopathy * Major congenital anomaly * Patients receiving diuretic therapy * Patients with obvious edema * Heart or liver failure, portal hypertension with acid * Pre-post operative patients * Infants receiving total parenteral nutritional therapy * Other: all conditions that require non-standard liquid content and quantities
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 420, 'type': 'ACTUAL'}}
Updated at
2023-07-27

1 organization

2 products

6 indications

Indication
Hyponatremia
Indication
Hypernatremia
Indication
Fluid Therapy
Indication
Salt